VISION: Defining Biomarkers of Chemotherapy & Immunotherapy Response and Validation of the Breast Cancer Therapeutic Response Predictive Algorithm for Early Triple Negative Breast Cancers

Background: Despite improvements in the treatment of Triple Negative Breast Cancer (TNBC), the cancer returns in half of the women and shockingly 40% are dead within 5 years of their initial cancer diagnosis. There is an urgent need to identify reliable biomarkers of response for chemotherapy and immunotherapy.
Study Aims: To update Concr's existing predictive algorithms specifically for use in women newly diagnosed with TNBC.
The plan is develop technology which will predict which drug the cancer will respond best to, treatment A vs. treatment B AND how the individual's prognosis could change if treatment A is chosen overtreatment B.
Study Design: The VISION study is a clinical study looking back in time (retrospective study), specifically focusing on women who were previously diagnosed with early Triple Negative breast cancer and received chemotherapy followed by curative breast surgery. The plan is to collect historical clinical data and previously collected cancer biopsy samples from up to 200 women in order to update Concr's existing treatment prediction algorithms. Hence there are no extra research biopsies needed in order to participate in the Study.
Study Sites: UK and Australia
Study Funding: This study is funded by the a Techbio company called Concr with support from Innovate UK (UK Government funding).

开始日期2024-05-01

申办/合作机构

Concr Pty Ltd

[+3]

100 项与 University of Durham 相关的临床结果

登录后查看更多信息

0 项与 University of Durham 相关的专利（医药）

登录后查看更多信息

30,894

项与 University of Durham 相关的文献（医药）

2025-08-15·Science Advances

Classic Maya response to multiyear seasonal droughts in Northwest Yucatán, Mexico

Article

作者: Henderson, Gideon M. ; Breitenbach, Sebastian F. M. ; Hodell, David A. ; James, Daniel H. ; Hoggarth, Julie A. ; Kwiecien, Ola ; Endsley, Erin A. ; Brenner, Mark ; Nicolson, John ; Lases-Hernández, Fernanda ; Iveson, Alexander A. ; Baldini, James U. L. ; Gallup, Christina D. ; Curtis, Jason H. ; Carolin, Stacy A. ; Rolfe, James ; Milbrath, Susan ; Ottley, Christopher J.

Protracted droughts may have contributed to sociopolitical upheaval and depopulation of cultural centers in the Maya Lowlands during the Terminal Classic Period (~800 to 1000 CE). Regional proxy climate records suggest multiple prolonged drought episodes during the Terminal Classic. The relationship between drought and response of individual sites, however, remains unclear because of large chronological uncertainties and poor temporal resolution of existing local paleoclimate inferences. We present a subannual rainfall record from northwest Yucatán, Mexico, derived from an annually laminated stalagmite spanning 871 to 1021 CE, with ±6-year age uncertainty. Interpretation of the stalagmite oxygen isotope record is supported by modern rain and drip water monitoring. Precisely dated droughts enable detailed analyses of timing and dynamics of regional human-climate interactions. Despite uncertainties in archaeological chronologies, these results suggest political activity at major northern Maya sites, including Chichén Itzá and Uxmal, declined at different times relative to droughts, implying differential cultural responses to climate stress.

2025-08-07·GENOME RESEARCH

ERC2.0 evolutionary rate covariation update improves inference of functional interactions across large phylogenies.

Article

作者: Francette, Alex Michael ; Meyer, Guillermo Hoffmann ; Grover, Aakash ; Smith, Martin ; Partha, Raghavendran ; Chikina, Maria ; Clark, Nathan ; Arndt, Karen M ; Little, Jordan H

Evolutionary rate covariation (ERC) is an established comparative genomics method that identifies sets of genes sharing patterns of sequence evolution, which suggests shared function. Whereas many functional predictions of ERC have been empirically validated, its predictive power has hitherto been limited by its inability to tackle the large numbers of species in contemporary comparative genomics data sets. This study introduces ERC2.0, an enhanced methodology for studying ERC across phylogenies with hundreds of species and tens of thousands of genes. ERC2.0 improves upon previous iterations of ERC in algorithm speed, normalizing for heteroskedasticity, and normalizing correlations via Fisher transformations. These improvements have resulted in greater statistical power to predict biological function. In exemplar yeast and mammalian data sets, we demonstrate that the predictive power of ERC2.0 is improved relative to the previous method, ERC1.0, and that further improvements are obtained by using larger yeast and mammalian phylogenies. We attribute the improvements to both the larger data sets and improved rate normalization. We demonstrate that ERC2.0 has high predictive accuracy for known annotations and can predict the functions of genes in nonmodel systems. Our findings underscore the potential for ERC2.0 to be used as a single-pass computational tool in candidate gene screening and functional predictions.

2025-08-01·CURRENT OPINION IN BIOTECHNOLOGY

Anaerobic microbial core for municipal wastewater treatment — the sustainable platform for resource recovery

Review

作者: Conall Holohan, B ; O'Flaherty, Vincent ; Smith, Adam L ; Keating, Ciara ; Robles, Angel ; Shin, Chungheon ; Chernicharo, Carlos L ; Hughes, Dermot ; Daigger, Glen ; Knörle, Ulrich ; Trego, Anna ; Rogalla, Frank ; Paissoni, Eleonora ; Szczuka, Aleksandra ; Bressani-Ribeiro, Thiago ; Galdi, Stephen M ; Soares, Ana

The requirement for carbon neutrality and bioresource recovery has shifted our views on water treatment from health and pollution avoidance to one of sustainability with water and nutrient circularity. Despite progress, the current process of wastewater treatment is linear, based on core aerobic microbiology, which is unlikely to be carbon neutral due to its large use of energy and production of waste sludge. Here, we outline a shift from aerobic to anaerobic microbiology at the core of wastewater treatment and resource recovery, illustrating the state-of-the-art technologies available for this paradigm shift. Anaerobic metabolism primarily offers the benefit of minimal energy input (up to 50% reduction) and minimal biomass production, resulting in up to 95% less waste sludge compared with aerobic treatment, which is increasingly attractive, given dialogue surrounding emerging contaminants in biosolids. Recent innovative research solutions have made ambient (mainstream) anaerobic treatment a ready substitute for the aerobic processes for municipal wastewater in temperate regions. Moreover, utilising anaerobic treatment as the core carbon removal step allows for more biological downstream resource recovery with several opportunities to couple the process with (anaerobic) nitrogen and phosphorus recovery, namely, potential mainstream anaerobic ammonium oxidation (anammox) and methane oxidation (N-DAMO). Furthermore, these technologies can be mixed and matched with membranes and ion-exchange systems, high-value biochemical production, and/or water reuse installations. As such, we propose the reconfiguration of the wastewater treatment plant of the futurewith anaerobic microbiology. Mainstream anaerobic treatment at the core of a truly sustainable platform for modern municipal wastewater treatment, facilitating circular economy and net-zero carbon goals.

项与 University of Durham 相关的新闻（医药）

2024-10-09

·plecotherapeutics.com

Pleco Therapeutics Announces Publication of Collaborative Research on Metal-Binding Amino Acids

Pleco Therapeutics is proud to announce the publication of a research paper, "Synthesis of Metal-Binding Amino Acids," in Organic & Biomolecular Chemistry. Authored by PhD-student Katherine Deck and Associate Professor Will Brittain from Durham University, UK. The paper outlines recently developed strategies for the synthesis of metal binding non-proteinogenic amino acids, which an essential part of ongoing efforts to explore novel therapies. Pleco’s support is mentioned under Acknowledgements, for which we thank the authors. This work is part of our ongoing collaborations with academic centres around the world, including Durham University, where our focus is on investigating basic mechanisms of chemoresistance. These developments align with Pleco Therapeutics' mission to enhance chemotherapy efficacy and overcome treatment resistance in cancer. We extend our congratulations to Katherine Deck and Will Brittain for their contribution. Click here for article

2024-09-27

·英国纽卡斯尔大学

中国线下招聘会圆满举办——欢迎了解英国纽卡斯尔大学的更多就业指导服务

本月，英国纽卡斯尔大学携手杜伦大学、华威大学、圣安德鲁斯大学和埃克塞特大学，一同在北京和上海举办了「2024中国线下招聘会」，帮助超过1000名毕业生顺利完成求职面试🎉！在这场为期三天的大型招聘会中，多家海内外知名企业雇主亲临现场，其中包括：特斯拉、汇丰、阿里云、伦敦证券交易所LSEG、京东、联想、戴尔、宁德时代、荣耀、雀巢、蒙牛、米哈游、英国文化教育协会（British Council）等。各大企业也提供了丰富的岗位选择，包括但不限于：算法、计算机、工程师、新能源、企业管培生、市场、媒体、教育等。多年来，英国纽卡斯尔大学始终致力于为已毕业的校友和在校学生们提供求职就业指导。除了此类大型线下招聘活动，学校也针对大家关心的「寻找实习与志愿机会」、「求职材料准备」和「创业支持」提供完备服务。 “2025年QS世界大学排名中，英国纽卡斯尔大学「就业能力」荣获五星评级。” 即刻下滑阅读，了解并用好英国纽卡斯尔大学的各类就业资源，制胜“金九银十”招聘季！ 🙋在读学生 🎓近三年毕业校友 💬 一对一咨询 ✏️ 个性化辅导 💡 就业研讨会 🤝 线下招聘会实习机会与志愿活动 🙌 在读本科生和研究生可申请 ✔️ 学期期间和暑期期间均提供实习机会 ⌚️ 暑期实习可以选择全职，也可根据个人情况灵活安排时间 💰 校园实习按小时提供酬劳，当地企业实习提供免税奖学金 💼 深入了解特定工作角色或领域，提前探索未来职业兴趣长按扫描下方二维码查找并申请实习机会简历撰写与面试指导 📒 简历与求职信撰写指导 📃 在线求职申请表填写辅导 🔍 LinkedIn领英个人资料填写指南 📝 涵盖逻辑、性格、心理、游戏式评估、各类专科测试的海量题库 🧑🏫 一对一面试辅导 📬 Offer接受及薪资洽谈指导创业扶持 💰 通过评选的创业项目可获得高达£3,000的创业启动资金 🙋 与拥有自主创业一手经验的求职顾问进行一对一会谈 👥 参加研讨会，认识志同道合的合作伙伴 💻 在纽卡斯尔Helix、Floe、TusPark、Northern Design Centre、PROTO等蓬勃发展的创业环境中自由成长长按扫描下方二维码了解创业扶持报名进行中｜留学生就业指导项目自2018年起，英国纽卡斯尔大学Career Service已连续六年举办「China Career Gateway中国留学生就业服务指导专项项目」，为超过1000名同学提供就业指导。 🔍 你将在项目中获得什么？全面了解中英两国职场掌握高效申请中英两国工作岗位的秘诀克服就业难题，在激烈的竞争中脱颖而出 2024年China Career Gateway活动将于10月7日重磅来袭，报名通道现已开启，欢迎同学们长按扫描下方二维码注册参加，为顺利斩获心仪Offer做好准备！ —— 更多精彩 —— —— 关注我们 —— —— 联系我们 —— 📪 邮箱｜China.IO@ncl.ac.uk ☎️ 电话｜ +44 191 208 6000 💻 官网｜www.ncl.ac.uk

高管变更

2024-08-22

·PMLiVE

Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat patients with early stages of the neurodegenerative disease, but has not been recommended by the National Institute of Health and Care Excellence (NICE) for use on the NHS in England and Wales. Leqembi (lecanemab) has been authorised by the MHRA to treat mild cognitive impairment and mild dementia due to AD in adults who have one or no copies of the apolipoprotein E4 gene. However, in a blow to patients, NICE has stated in draft guidance that the drug’s benefits are “too small to justify the costs”. An estimated 982,000 people in the UK are living with dementia and AD accounts for the majority of cases. Administered intravenously in a healthcare setting every two weeks, Leqembi works by binding to and reducing clumps of amyloid beta protein that form plaques in the brain. The MHRA’s decision makes Leqembi the first medicine to be licensed in the UK that has been shown to slow progression of the disease and was supported by results from the late-stage Clarity AD trial, in which Leqembi reduced clinical decline by 27% compared with placebo at 18 months. Eisai, which serves as the lead for the drug’s development and regulatory submissions globally, also recently presented positive three-year data from an open-label extension of the study. Despite the improvements observed, an independent NICE committee said: “The costs of providing the treatment, including fortnightly infusions in hospital and intensive monitoring for side effects, combined with the relatively small benefits it provides to patients means it cannot be considered good value for the taxpayer.” Alzheimer’s Research UK’s chief executive, Hilary Evans-Newton, described the news as “bittersweet”. “It’s a remarkable achievement that science is now delivering licensed treatments that can slow down the devastating effects of Alzheimer’s, rather than just alleviating its symptoms. However, it’s clear our health system isn’t ready to embrace this new wave of Alzheimer’s drugs,” she said. Professor Andy Whiting, emeritus professor at Durham University and chief executive officer and co-founder of Nevrargenics, a Durham spinout company developing drugs for neurodegenerative diseases including Alzheimer’s, said in response to today’s news: “While the MHRA approval of [Leqembi] is obviously a step forward for the pharma industry, the NICE rejection reinforces the need for the biotech and pharma community to focus on better balancing of cost versus effectiveness in drug development. “[Leqembi] only targets the symptoms – the plaques – rather than the cause of those plaques. For a new drug to provide value, the impact needs to be higher, which requires our industry to develop bolder drugs for neurodegeneration that target the cause of the disease, not just the symptoms.” NICE’s independent committee will consider responses from a public consultation at a second meeting later this year before producing its final recommendations.